CURRENT RESPECTIVE PLACE OF SURGERY AND PERMANENT INTRACARDIAC PACING IN THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY

被引:0
作者
MILLAIRE, A
DEGROOTE, P
DECOULX, E
DUCLOUX, G
机构
来源
ANNALES DE CARDIOLOGIE ET D ANGEIOLOGIE | 1995年 / 44卷 / 05期
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Surgery and cardiac pacing are the two main non-drug treatments for hypertrophic cardiomyopathy. Various surgical techniques have been propsed over the last 35 years : myotomy, myotomy-septal myomectomy, isolated mitral valve replacement, heart transplantation. Patients eligible for surgery are those with severe symptoms (NYHA stage III or IV) and refractory or no longer responding to drug treatment. The choice between the various techniques is based on morphological and haemodynamic criteria (significant subaortic gradient associated with increased septal thickness, severe and/or organic mitral regurgitation, either isolated or associated with obstruction, or less severe or heterogeneous septal thickness [<18 mm]) or therapeutic criteria (failure of primary myomectomy, depletion of all surgical possibilities). Analysis of the results of surgery is complicated by the variety of techniques performed and the experience of the various teams. The operative mortality was markedly decreased (between 2 and 11 % at the present time); the complications of myomectomy (ventricular septal defect, disturbances of conduction requiring continuous pacing) are still frequent. Intraoperative transoesophageal ultrasonography could help to further decrease the operative risk. Surgery improves functional symptoms and exercise tolerance. This beneficial effect appears to be more marked, more frequent and more lasting than that of medical treatment. Surgical treatment does not ensure permanent cure, as the symptoms related to pathophysiological abnormalities other than intraventricular obstruction (abnormalities of diastolic filling, myocardial ischaemia, arrhythmias) may develop subsequently. No controlled trial has demonstrated a favourable effect survival. Continuous pacing, introduced more recently, can now be considered to be a therapeutic method in its own right. The benefit provided by continuous pacing appears to be equivalent to that of surgery (on symptoms, exercise capacity, intraventricular gradient) with a negligible risk compared to that of surgery. This has led a number of authors to propose continuous pacing as second-line treatment after failure of medical treatment and before resorting to surgery.
引用
收藏
页码:226 / 233
页数:8
相关论文
共 50 条
  • [41] Effects of permanent DDD pacing over diastolic function in the severe obstructive hypertrophic cardiac cardiomyopathy.: An 8-year experience
    Tascón, J
    Albarrán, A
    Gascuena, R
    Hernández, F
    Alonso, M
    Andreu, J
    Dalmau, R
    Pombo, M
    [J]. EUROPEAN HEART JOURNAL, 2000, 21 : 414 - 414
  • [42] Comparison of av sequential pacing and transcoronary myocardial ablation (TASH-procedure) in the treatment of hypertrophic obstructive cardiomyopathy
    Boekstegers, P
    Steinbigler, P
    [J]. CIRCULATION, 1997, 96 (08) : 1202 - 1202
  • [43] IMPACT OF DUAL-CHAMBER PERMANENT PACING IN PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY WITH SYMPTOMS REFRACTORY TO VERAPAMIL AND BETA-ADRENERGIC BLOCKER THERAPY
    FANANAPAZIR, L
    CANNON, RO
    TRIPODI, D
    PANZA, JA
    [J]. CIRCULATION, 1992, 85 (06) : 2149 - 2161
  • [44] Current state of the roles of alcohol septal ablation and surgical myectomy in the treatment of hypertrophic obstructive cardiomyopathy
    Douglas, John S., Jr.
    [J]. CARDIOVASCULAR DIAGNOSIS AND THERAPY, 2020, 10 (01) : 36 - 44
  • [45] Redistribution of myocardial perfusion during permanent dual chamber pacing in symptomatic non-obstructive hypertrophic cardiomyopathy: A quantitative positron emission tomography study
    Posma, JL
    Blanksma, PK
    vanderWall, EE
    [J]. HEART, 1996, 75 (05) : 522 - 524
  • [46] Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy - A randomized, double-blind, crossover study (M-PATHY)
    Maron, BJ
    Nishimura, RA
    McKenna, WJ
    Rakowski, H
    Josephson, ME
    Kieval, RS
    [J]. CIRCULATION, 1999, 99 (22) : 2927 - 2933
  • [47] Morbidity and resource usage after myectomy- or pacing-treatment in hypertrophic obstructive cardiomyopathy: A case-control study
    Javidgonbadi, Davood
    Andersson, Bert
    Abdon, Nils-Johan
    Ostman-Smith, Ingegerd
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 322 : 197 - 203
  • [48] Pathoanatomic Findings and Treatment During Hypertrophic Obstructive Cardiomyopathy Surgery: The Role of Mitral Valve in LVOT Obstruction
    Raffa, Giuseppe M.
    Romano, Giuseppe
    Turrisi, Marco
    Morsolini, Marco
    Gentile, Giovanni
    Sciacca, Sergio
    Armaro, Alessandro
    Stringi, Vincenzo
    Mattiucci, Gabriella
    Magro, Serena
    Cosentino, Fabiola
    Clemenza, Francesco
    Pilato, Michele
    [J]. HEART LUNG AND CIRCULATION, 2019, 28 (03) : 477 - 485
  • [49] Late sodium current inhibitors for the treatment of inducible obstruction and diastolic dysfunction in hypertrophic cardiomyopathy: a study on human myocardium
    Ferrantini, C.
    Coppini, R.
    Pioner, J. M.
    Gentile, F.
    Mazzoni, L.
    Rossi, A.
    Tesi, C.
    Belardinelli, L.
    Olivotto, I.
    Cerbai, E.
    Mugelli, A.
    Poggesi, C.
    [J]. CARDIOVASCULAR RESEARCH, 2016, 111 : S35 - S35
  • [50] DDD Pacing Therapy Could Serve as a Dual Purpose Treatment in Hypertrophic Obstructive Cardiomyopathy -A Case Report Which Suggests the Importance of Lead Position and the Mechanism
    Nakahara, Shiro
    Takayanagi, Kan
    Toratani, Noritaka
    Seino, Masanori
    Sakai, Yoshihiko
    Kobayashi, Sayuki
    Matsumoto, Kazuo
    [J]. JOURNAL OF ARRHYTHMIA, 2007, 23 (03) : 245 - 249